Key Highlights

  • Recursion Pharmaceuticals logged $18.6 million of revenue, roughly 3.6x last year's level (calculated), helped by a $10.0 million milestone.
  • Syndax Pharmaceuticals reported $83.3 million in revenue, up 82%, with Revuforj supplying $60.7 million.
  • Hinge Health delivered $235.0 million, up 52%, and raised full-year 2026 Revenue guidance to $879 million through $881 million.
  • Axsome Therapeutics generated $259.7 million in revenue, up 51.9% (calculated), and trimmed the red ink to $12.9 million.
  • Neurocrine Biosciences brought in $1,122.7 million, a 41.2% increase, and raised its 2026 INGREZZA target into a band of $2.9 billion through $2.925 billion.

Five Healthcare Names Ranked by Third Quarter Sales Expansion

Five healthcare and biotech firms are placed below by year-over-year sales growth for the third quarter of 2026, using results released Nov 2, 2026. Recursion Pharmaceuticals (NASDAQ:RXRX) holds first place at 258.5% (calculated), on $18.6 million of revenue, compared with $5.2 million twelve months before. Syndax Pharmaceuticals (NASDAQ:SNDX) takes second with 82% growth to $83.3 million, while Hinge Health (NYSE:HNGE) sits third at $235.0 million, a 52% increase.

Fourth place goes to Axsome Therapeutics (NASDAQ:AXSM), which reported $259.7 million, a 51.9% gain on a calculated basis. Neurocrine Biosciences (NASDAQ:NBIX) completes the group with $1,122.7 million, a 41.2% advance. Hinge's rounded 52% and Axsome's 51.9% sit almost level, which leaves third and fourth separated by a slim gap.

Base sizes vary a lot. Recursion's quarter is the smallest here and Neurocrine's the largest, so the leading growth figure starts from a modest base. Only Hinge Health and Neurocrine posted positive net income, while the remaining trio recorded losses.

1. Recursion Pharmaceuticals: Milestone Income Lifts Sales While the Loss Narrows

Recursion submitted its quarterly filing on Nov 2, 2026, reporting $18.6 million of revenue for the third quarter, up from $5.2 million. The company credited mainly a $10.0 million milestone tied to a Partnership with a large drug developer. The clinical-stage firm applies AI, automation and biological data to find medicines. Nine-month revenue totaled $32.7 million, a 16% decline from $39.1 million.

The red ink shrank by 27%, landing at $119.0 million ($0.22 a share), while Research and Development spending dropped to $99.1 million from $121.1 million. Cash on hand came to $549.9 million; management judges that enough to support operations for a minimum of 12 months, though the filing says extra financing will eventually be necessary. The REC-4881 data show 13 of 15 adult patients with a smaller polyp load at the 12-week mark.

2. Syndax Pharmaceuticals: Revuforj Sales and Collaboration Income Lift a Quarter

Quarterly sales at Syndax reached $83.3 million, climbing from $45.9 million a year earlier. Revuforj, a menin inhibitor used for relapsed or refractory acute leukemia carrying certain genetic alterations, generated $60.7 million in net product revenue, along with approximately 1,700 prescriptions and close to 300 new patients. Collaboration income tied to Niktimvo reached $22.6 million, and the partner recorded net sales of $67 million for that product.

Losses shrank to $49.4 million ($0.55 a share), against $60.7 million ($0.70) in the earlier period. Research and development spending increased 19.9% (calculated), reaching $67.5 million. Cash and investments combined totaled $551 million; a June 2026 convertible note offering of $250.0 million added to that total. Full-year spending on research, development, selling and administration is still projected near $400 million for 2026.

3. Hinge Health: Stronger Member Yield Drives a Beat and a Raised Outlook

Hinge Health's third quarter revenue reached $235.0 million, up from $154.2 million and above the $223 million to $225 million the company had forecast for itself. Leadership said the excess came entirely from billings outperformance tied to stronger yield. Yield, defined as the proportion of eligible members who sign up and stay engaged, drove that excess. The company offers online care for musculoskeletal problems and has expanded into migraine and GI programs.

GAAP Earnings totaled $57.4 million ($0.66 a diluted share), up from a $1.8 million Deficit the year before. Non-GAAP Operating Margin climbed to 33% from 20%, while free Cash Flow hit $112.7 million. The full-year 2026 revenue range moved up to $879 million through $881 million, previously $856 million through $860 million, and fourth quarter sales are slated at $249 million to $251 million.

4. Axsome Therapeutics: Auvelity Momentum Behind a 51.9% Revenue Gain

Axsome's revenue for the third quarter came to $259.7 million, which compares with $171.0 million previously. Auvelity sales hit $207.6 million compared with $136.1 million, supported by a June 2026 approval for agitation linked to Alzheimer's disease. Leadership said the commercial lineup now exceeds a $1 billion annualized sales pace.

Shareholder losses narrowed to $12.9 million, or $0.25 a share, from $47.2 million ($0.94). Selling, general and administrative expenses climbed to $203.1 million from $150.2 million, reflecting the product debut, nationwide consumer Advertising and a bigger sales force. Cash on hand reached $313.9 million, and $190.0 million had been drawn on its Credit facility.

5. Neurocrine Biosciences: INGREZZA, CRENESSITY and VYKAT XR Lift Sales Above $1.1 Billion

Sales at Neurocrine came in at $1,122.7 million, a 41.2% increase from $794.9 million. INGREZZA contributed $801.5 million, CRENESSITY sales grew past double their prior level to $210.8 million, and VYKAT XR, added through a May 2026 acquisition, brought in $106.7 million. Leadership pointed to a timing lift of $20 million in INGREZZA orders, which should unwind during the fourth quarter.

Profit came to $206.5 million ($1.96 a diluted share), compared with $209.5 million ($2.04) a year earlier, as $52.3 million of unrealized losses on Equity holdings offset a $30.6 million gain. R&D costs rose to $351.8 million, up from $250.0 million. The full-year INGREZZA outlook moved up to between $2.9 billion and $2.925 billion.

Growth Averages and Dollar Gains Across Five Reporters

Mean growth across the five is 97.1% (calculated); without Recursion, the remaining four average 56.8% (calculated). Pooled revenue comes to $1,719.3 million (calculated), and Neurocrine contributes 65.3% of it (calculated).

Measured in dollars, the picture shifts. Neurocrine's increase equals $327.8 million (calculated), against Recursion's $13.4 million (calculated), despite Recursion leading on percentages. Taken together, the three unprofitable companies lost $181.3 million (calculated). Hinge's growth rate is a rounded company figure, while the Recursion and Axsome percentages are derived from reported numbers.

What to Watch Next: Neurocrine's December R&D Event, Axsome's FDA Target and Syndax Leadership Shift

Neurocrine plans an R&D Day in New York on Dec 15, 2026, and intends to give formal 2027 INGREZZA guidance in February. Axsome's regulatory deadline is May 1, 2027, for AXS-12 in cataplexy linked to narcolepsy, and a Phase III readout in binge eating disorder is expected in the first quarter of 2027.

Syndax welcomes a new finance chief on Nov 9, 2026, and fresh Revuforj data are slated for a December hematology conference. Hinge Health's president steps away from the post on Jan 1, 2027 and takes a board seat Jan 4, 2027. Recursion's materials point to a registrational trial start and expansion data during the second half of 2027, though no exact date is given.